ProQR reveals positive results from Phase 1/2 trial of Sepofarsen
Category: #health  By Pankaj Singh  Date: 2019-10-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

ProQR reveals positive results from Phase 1/2 trial of Sepofarsen

Leber congenital amaurosis (LCA) is a very rare eye condition that can be seen in newborn babies. Currently, the disease doesn’t have a permanent therapy, however, many pharma companies are now making some advancements to treat this disease.

ProQR Therapeutics N.V., a biotechnology company based in Netherlands, is one such firm that has recently revealed encouraging top-line findings from the PQ-110-001 study, a dose range finding, first-in-human trial Phase 1/2 trials of sepofarsen (QR-110) in patients suffering from LCA10 (Leber’s congenital amaurosis 10) due to the mutation of p.Cys998X in CEP290 gene.

Speaking on the move, Stephen R. Russell, MD, Principal Investigator, the University of Iowa, said that the trial has established that patients getting sepofarsen showed a clinically meaningful development in vision, meanwhile in a few situations the patient showed a groundbreaking improvement in vision which could be said as life-changing.

As per David Rodman, M.D., Executive Vice President of Research & Development, ProQR, the company is delighted with the reported data from the Phase 1/2 trial, where in LCA10 patients demonstrated a durable and rapid improvement in vision after regular dosage of sepofarsen.

Moreover, the positive data from this trial further strengthens the company’s trust in the design of the Phase 2/3 study, which might act as the primary registration trial for the drug program, adds Rodman

Reportedly, ProQR has also prior made some advancements in this field when it revealed that sepofarsen was cleared for the PRIME (PRIority Medicines) program by the EMA (European Medicines Agency).

Commenting on the approval, Daniel A. de Boer, Chief Executive Officer, ProQR, said that the agency’s decision to provide PRIME access to its therapy further establishes the grueling demand for modern medicine to treat LCA10 patients, which simplifies the rigorous selection process of the therapy.

Furthermore, the company hopes to expand sepofarsen’s reach to patients of LCA10 as soon as possible, he added.

Source Credit: https://ir.proqr.com/news-releases/news-release-details/proqr-announces-positive-top-line-results-phase-12-study



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...